单位：[1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.肿瘤科华中科技大学同济医学院附属同济医院
Precise targeting has become the main direction of anti-cancer drug development. Trophoblast cell surface antigen 2 (Trop-2) is highly expressed in different solid tumors but rarely in normal tissues, rendering it an attractive target. Trop-2-targeted antibody-drug conjugates (ADCs) have displayed promising efficacy in treating diverse solid tumors, especially breast cancer and urothelial carcinoma. However, their clinical application is still limited by insufficient efficacy, excessive toxicity, and the lack of biological markers related to effectiveness. This review summarizes the clinical trials and combination therapy strategies for Trop-2-targeted ADCs, discusses the current challenges, and provides new insights for future advancements.
基金：
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2020MS-1039).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|3 区医学
小类|3 区药物化学3 区药学
最新[2025]版：
大类|3 区医学
小类|2 区药学3 区药物化学
第一作者：
第一作者单位：[1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Jiang Yizhi,Zhou Haiting,Liu Junxia,et al.Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs[J].Pharmaceuticals (Basel, Switzerland).2024,17(5):doi:10.3390/ph17050652.
APA：
Jiang Yizhi,Zhou Haiting,Liu Junxia,Ha Wentao,Xia Xiaohui...&Xiong Huihua.(2024).Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs.Pharmaceuticals (Basel, Switzerland),17,(5)
MLA：
Jiang Yizhi,et al."Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs".Pharmaceuticals (Basel, Switzerland) 17..5(2024)
